Inside informationEnglish
Transgene and NEC Present Durable Disease-Free Survival and Sustained T Cell Responses at 24 Months with Individualized Cancer Vaccine TG4050
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Transgene S.A.
- Filed
- 01/06/2025, 19:15
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 119814_20250601